Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.

Chan, S; Davidson, N; Juozaityte, E; Erdkamp, F; Pluzanska, A; Azarnia, N; Lee, L W

Chan, S; Davidson, N; Juozaityte, E; Erdkamp, F; Pluzanska, A; Azarnia, N; Lee, L W.

Affiliation

Chan S; City Hospital, Nottingham, UK. ytschan@innotts.co.uk

Ann Oncol ; 15(10): 1527-34, 2004 Oct.

Article in En | MEDLINE | ID: mdl-15367414

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Breast Neoplasms/pathology; Cyclophosphamide/administration & dosage; Disease Progression; Doxorubicin/administration & dosage; Epirubicin/administration & dosage; Female; Granulocyte Colony-Stimulating Factor/administration & dosage; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left/chemically induced

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2004 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links